Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Markets and distributes specialty, artisanal and farmstead cheese products

Pharmaceutical concern

G.D. Searle, LLC is a wholly owned trademark of Pfizer. It is currently used mainly as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle). Prior to its 1985 merger with Monsanto, Searle was a company focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified, and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation, and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management, and commercialization) to ultimately generate Ligand revenue.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

American Home Products LLC operates as a holding company which engages in the acquisition of niche manufacturers and distributors of functional and decorative architectural building and renovation products. These products are provided to the residential markets. The company was founded in 2014 and is headquartered in Van Nuys, CA.

Akzo Nobel NV is a holding company, which engages in the manufacture and sale of coating and paint products. engages in the production and marketing of paints and coatings. It operates through the following segments: Decorative Paintings, Performance Paintings, and Corporate and Others. The Decorative Paints segment manufactures and supplies a range of interior and exterior decoration and protection products for professional and do-it-yourself markets. The Performance Coatings segment produces automotive and aerospace; industrial; marine and protective; and powder coatings. The company was founded in 1792 and is headquartered in Amsterdam, Netherlands.

Arstat Pharmaceuticals ("Arstat") is a world-class pharmaceutical company involved in the development of novel women's health products. Arstat's products have proven efficacy and safety and focus on major areas of unmet medical needs in women's health: contraception for overweight and obese women, uterine fibroids and endometriosis, and painful and heavy menstrual periods. Arstat's high-value portfolio is protected by 10 granted U.S. patents (more pending) and a European (EPO) patent. The pipeline includes 4 drug candidates with proven efficacy and safety. Two products are Phase III-ready (confirmed by the FDA), two other products are ready for Phase IIb. An addressable US market is approximately 50 million women with projected peak US net sales of $3.0 – 4.0 billion. The targeted global market may exceed 800 million women with significant European and worldwide sales. Arstat's most valuable asset, Nuvocept, is the first and only oral contraceptive designed explicitly for overweight and obese women. The FDA has already endorsed an unprecedented clinical program and a potentially unique label. Nuvocept is expected to dominate a multi-billion-dollar segment of the U.S. contraceptive market The Founder and CEO of Arstat Pharmaceuticals, Arkady Rubin, has over 30 years of industry experience (J&J, Pfizer) and is the co-inventor of Ortho Tri-Cyclen Lo, the best-selling oral contraceptive in the U.S. with peak sales exceeding $500 million per year. Arstat is raising a seed financing round to hire key executives, assemble a top-notch Board of Directors ahead of a $50.0 million public offering one year later, potentially in conjunction with a strategic partnership or collaboration. Proceeds raised in the public offering would allow Arstat to advance its Phase III candidates through NDA filing, FDA approval, and sale or out-licensing in 3 - 3.5 years from the initial financing round as well as complete Phase IIb studies for its remaining candidates. Conservative estimates of the fair value of Arstat's product portfolio at the time of the public offering are between $500 – $800 million.

Manufactures pharmaceuticals and diagnostic substances

Pantarhei Bioscience BV (PRB) is a limited liability company (Besloten Vennootschap) located in the Netherlands focussing on the development of innovative concepts for woman’s health and hormone-related cancer treatments. PRB has founded a subsidiary company – Pantarhei Oncology (PRO) – to develop treatments for Endocrine Cancer. PRB has developed a product pipeline based on its ability to identify novel medical uses of existing molecules, drugs, hormones, biologicals and combinations thereof in these areas of medicine. The main areas of expertise of PRB are reproductive hormone related treatments and diseases such as contraception and menopausal hormone therapy (MHT). The main areas of expertise of PRO are breast cancer, prostate cancer and ovarian cancer . PRB develops patent protected new treatment concepts up to proof-of-concept (PoC) in the human (phase II). Using existing molecules often provides first evidence of safety. The business model of the Pantarhei companies is based on creating intellectual property (IP) of new concepts ad inventions, in-house project management and outsourcing of all research and development activities. After successful PoC, data and IP are licensed out to a licensee or partner for completion of clinical development (phase III), regulatory approval and sales and marketing by a licensee/partner.

Glaxo Laboratories Ltd., part of GSK Plc, is a company headquartered in London, UK. The firm wholesales pharmaceutical goods. It was founded in 1929.

Laboratoire HRA Pharma SA manufactures and distributes pharmaceutical products. Its products include contraceptive pills such as the pill of two days later and EllaOne. The company was founded by Andre Ulmann in 1996 and is headquartered in Paris, France.

SyntheX created a novel cell-based, synthetic biology-driven drug selection platform, that allows for the efficient synthesis and identification of peptides and macrocycles that selectively disrupt intracellular protein-protein interactions of interest. Although the platform has broad application, the initial focus is on oncology. Targets are selected based on the concepts of synthetic lethality and oncogene addiction, with the first program focused on DNA damage repair and working through a novel cell death mechanism that was uncovered.

Jenapharm GmbH & Co. KG manufactures and distributes pharmaceutical products. It offers cures for erectile dysfunction, testosterone deficit, and hyperactivity. It also provides contraceptives, menopause pills, and food supplements. The company was founded in 1950 and is headquartered in Jena, Germany.

Predictive Therapeutics LLC specializes in the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. It develops, commercializes, acquires, and invests in technologies involved in novel molecular diagnostic and therapeutic healthcare products. The company is headquartered in Salt Lake City, UT.